Eriguchi M, Mathé G
Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):93-7.
Two mathematical models can approximate the survival curves for malignant diseases. The models identify the segments of the survival curve. Also, the hazard function of the curve and the confidence intervals of the curve could be calculated. First, we studied the survival-after-relapse curve of malignant melanoma. The curve of chemo-immunotherapy showed three segments and that for immunotherapy had two segments. The immunotherapy showed its effect in the early period of treatment. Second, the disease-free survival curves for adjuvant therapies of breast cancer were compared. In the Oncofrance trial, a combination of adriamycine, vincristine, cyclophosphamide (C) and 5-fluoro-uracil (F) (AVCF) was superior to a combination of C, methotrexate and F (CMF) in all the periods of the therapy. In Lacour's trial, poly A-poly U was more effective than the no treatment in the middle and late period. In Bonadonna's trial, CMF was superior to no treatment in the early period. Third, the survival curves for immunotherapy versus non-immunotherapy of stomach cancer were analysed. Comparison of the confidence intervals of each curve clarified that no significant difference could be found between them.
两种数学模型可以近似恶性疾病的生存曲线。这些模型可识别出生存曲线的各个部分。此外，还能计算出曲线的风险函数以及曲线的置信区间。首先，我们研究了恶性黑色素瘤复发后的生存曲线。化学免疫疗法的曲线显示有三个部分，而免疫疗法的曲线有两个部分。免疫疗法在治疗早期就显示出了效果。其次，对乳腺癌辅助治疗的无病生存曲线进行了比较。在法国肿瘤研究试验中，阿霉素、长春新碱、环磷酰胺（C）和5-氟尿嘧啶（F）（AVCF）的联合疗法在治疗的各个阶段都优于C、甲氨蝶呤和F（CMF）的联合疗法。在拉库尔试验中，聚A-聚U在治疗中期和后期比不治疗更有效。在博纳多纳试验中，CMF在治疗早期优于不治疗。第三，分析了胃癌免疫疗法与非免疫疗法的生存曲线。对每条曲线置信区间的比较表明，两者之间未发现显著差异。
